Replies to post #99050 on Biotech Values

[genisi]

We should tell the person who takes care of the scientific calendar s/he missed the The International AIDS Conference - http://www.aids2010.org/ where TMC278 data will also be presented.

[ciotera]

Kaletra is such a dog it can't be salvaged.
The whole point is to construct a more tolerable regimen by getting rid of the nuke backbone. But using Kaletra just brings its own host of side-effects.
I'm more interested in seeing the results of the various unboosted Reyataz/Isentress studies.

[Elroy Jetson]

I believe the short 48 week duration of the ABT study does not capture what I believe is the the durability of Truvada when compared with Isentress, which has a low resistance hurdle when compared with Truvada.

I believe part of this is due to the relative half-life of the drugs, Viread with median 17 hours serum and 60 hour intracellular, compared with 9 hours serum for Isentress and an ill-defined intracellular range of up to 29 hours.

There are known advantages of reduced viral fitness resulting from adapted viral resistance to the shorter-live Emtriva co-drug in Truvada, or the closely related Epivir.

The other portion of reduced Isentress durability lies in the limited number of mutations required to obtain resistance.

Side-effect wise you have kidney toxicity with Viread compared with inflammatory symptoms in many who try Isentress.

It would be great if someone developed a superior complementary therapy to Viread, but I don't see that currently among the contenders.
.